What is the diagnostic workup for systemic lupus erythematosus?

Diagnostic Workup for Systemic Lupus Erythematosus

The diagnostic workup for SLE begins with ANA testing at ≥1:80 titer by indirect immunofluorescence on HEp-2 cells as the mandatory entry criterion, followed by a double-screening strategy for anti-dsDNA antibodies using a sensitive solid-phase assay first, then confirmatory Crithidia luciliae immunofluorescence test (CLIFT), plus comprehensive anti-ENA panel and complement levels. 1

Initial Serological Testing

Antinuclear Antibodies (ANA)

• ANA testing at ≥1:80 titer by indirect immunofluorescence on HEp-2 cells is the required entry criterion per EULAR/ACR 2019 classification criteria 1
• The 1:80 cutoff has 74.7% specificity for SLE, which is relatively low, so positive results must be interpreted with clinical context 1
• In unselected populations, use 1:160 dilution as the cutoff to improve specificity 1
• ANA-negative SLE is extremely rare; if clinical suspicion remains high despite negative ANA, request specific antibody testing regardless 1
• Document the ANA pattern (homogeneous, speckled, nucleolar, centromere) and method used in the report 1

Anti-dsDNA Antibodies: Double-Screening Strategy

Use a sequential two-step approach for anti-dsDNA testing: 1

1. First step: Perform a last-generation solid-phase assay (SPA) such as FEIA (fluorescence enzyme immunoassay) for high sensitivity
2. Second step: Confirm positive SPA results with CLIFT for high specificity

Interpretation algorithm for anti-dsDNA double screening: 1

• SPA negative + CLIFT negative: Report as negative anti-dsDNA; SLE diagnosis unlikely
• SPA positive + CLIFT positive: Strong evidence for SLE; proceed with diagnosis
• SPA positive + CLIFT negative: Neither confirms nor excludes SLE; consider anti-nucleosome antibodies (83.33% sensitivity, 96.67% specificity for SLE) and antiphospholipid antibodies (present in 30-40% of SLE patients) 1
• SPA negative + CLIFT positive (rare): Repeat testing in new sample; if inconsistency persists, base diagnosis on clinical characteristics and follow patient periodically 1

Anti-ENA (Extractable Nuclear Antigen) Panel

When ANA is positive, confirmatory anti-ENA testing is mandatory: 1

• Anti-Sm (Smith): Highly specific for SLE
• Anti-RNP (ribonucleoprotein): Associated with mixed connective tissue disease overlap
• Anti-Ro/SSA: Present in 30-40% of SLE; critical before pregnancy (neonatal lupus risk) 1
• Anti-La/SSB: Often accompanies anti-Ro
• Anti-ribosomal P: Associated with neuropsychiatric SLE 1

Baseline Comprehensive Laboratory Panel

At initial evaluation, obtain: 1

Immunological Tests

• ANA, anti-dsDNA, anti-Sm, anti-RNP, anti-Ro, anti-La 1
• Antiphospholipid antibodies (anticardiolipin, anti-β2GP1, lupus anticoagulant) - essential before pregnancy, surgery, transplant, or estrogen-containing treatments 1
• Complement levels: C3, C4 1
• Anti-C1q antibodies if lupus nephritis suspected (present in nearly 100% of active lupus nephritis; excellent negative predictive value) 1

Hematologic and Chemistry Tests

• Complete blood count (assess for cytopenias) 1
• Erythrocyte sedimentation rate 1
• C-reactive protein 1
• Serum albumin 1
• Serum creatinine or estimated glomerular filtration rate (eGFR) 1

Urinalysis

• Urinalysis with microscopy 1
• Urine protein/creatinine ratio or 24-hour proteinuria 1
• If persistently abnormal urinalysis or raised creatinine: Obtain renal ultrasound and consider kidney biopsy 1

Organ-Specific Assessments

Renal Evaluation

For suspected lupus nephritis: 1

• Urine protein/creatinine ratio (or 24-hour proteinuria)
• Urine microscopy for cellular casts
• Anti-dsDNA and complement (C3, C4) levels
• Anti-C1q antibodies (nearly 100% present in active lupus nephritis) 1
• Renal ultrasound
• Kidney biopsy for definitive classification if proteinuria persists or creatinine elevated 1

Neuropsychiatric Assessment

Screen for: 1

• Seizures, paresthesias, numbness, weakness, headache, depression
• Cognitive impairment: attention, concentration, word-finding, memory difficulties (ask about multitasking problems, household task difficulties) 1
• If cognitive impairment suspected, perform detailed neuropsychological testing 1

Mucocutaneous Evaluation

Classify lesions as: 1

• LE-specific (malar rash, discoid lesions, subacute cutaneous lupus)
• LE-nonspecific
• LE mimickers
• Drug-related
• Assess activity and damage using validated indices (CLASI - Cutaneous Lupus Disease Area and Severity Index) 1

Special Situations

Anti-dsDNA Negative Lupus Nephritis

In patients with biopsy-proven lupus nephritis but negative anti-dsDNA: 1

• Use anti-nucleosome antibodies for disease monitoring 1
• Consider anti-histone antibodies (H1, H2A, H2B, H3, H4) if drug-induced lupus excluded 1

Pre-Pregnancy Evaluation

Before pregnancy, re-evaluate if previously negative: 1

• Anti-Ro and anti-La antibodies (neonatal lupus and congenital heart block risk)
• Antiphospholipid antibodies (pregnancy loss risk)

Common Pitfalls to Avoid

• Do not use ANA alone for diagnosis: The 1:80 cutoff has only 74.7% specificity; always obtain confirmatory testing 1
• Do not repeat ANA for disease monitoring: ANA does not correlate with disease activity; use anti-dsDNA and complement instead 1
• Do not rely on single anti-dsDNA method: The double-screening strategy (SPA then CLIFT) minimizes false positives and false negatives 1
• Do not delay kidney biopsy: In persistently abnormal urinalysis or elevated creatinine, biopsy is essential for classification and treatment planning 1
• Do not ignore antiphospholipid antibodies: Present in 30-40% of SLE patients and critical for pregnancy, surgery, and thrombosis risk assessment 1

Laboratory Reporting Standards

Laboratories should: 1

• Report the method used for each test
• Use international units (IU) when available for standardization
• Provide interpretation guidance beyond numerical values
• Include clinical context in result interpretation when provided